HomeWebinarsNanomedicine – Translating Drug Delivery Formulations to Advance Drug Discovery

Nanomedicine – Translating Drug Delivery Formulations to Advance Drug Discovery

Webinar

What Does it Cover?

Advancements in the field of drug discovery have led to more drug candidates with high potency and selectivity but with increased molecular weights and hydrophobicity. Nanoformulations, including liposomes, polymeric/inorganic nanoparticles, and emulsions, have tremendous potential to improve both solubility and bioavailability of drug candidates. However, successful use of nanoformulations in preclinical drug development requires reproducible and scalable synthesis methods and the ability to rapidly screen and optimize formulations. In this talk, we will explore formulation technologies for delivering small molecules and biologics and highlight the features of NanoFabTx™ developed in partnership with Dolomite Microfluidics. This platform enables reproducible synthesis of nanoformulations using conventional nanoprecipitation and advanced microfluidics-based synthesis techniques.

Key Learning Objectives

  • Applications of NanoFabTx™ formulation platform
  • Methods to make nanoparticles or microparticles by microfluidics
  • Methods for drug formulation using microfluidics
  • Materials screening to develop nanoformulations
  • Drug loading and characterization

Speakers

Nicolynn Davis, Ph.D.

MilliporeSigma

Head of Materials Science Product Innovation

She received her Ph.D. in Chemical Engineering at Northwestern University and was a Postdoctoral Fellow at Stanford University where she developed novel biomaterials for applications in tissue engineering, cell transplant, and drug delivery. Her research interests include 3D Bioprinting, novel drug delivery technologies, biomaterials for regenerative medicine and innovations in nanomaterials.

Rajiv Kumar, Ph.D.

MilliporeSigma

Technical Lead and Senior Formulation Scientist

He received his Ph.D. in Chemistry from University of Delhi, India, followed by his post-doctoral fellowship at University at Buffalo where he developed different nanoparticle formulations for applications in drug delivery and imaging. During his research at Northeastern University and Harvard Medical School, he designed various nanoparticle and implants-based drug delivery systems for combined chemoradiation therapy. He has 50+ peer-reviewed publications on nanoparticles-based formulations in cancer imaging and drug delivery applications.

Ben Knappett, Ph.D.

Dolomite Microfluidics

Head of Scientific R&D

He holds a Ph.D. from the University of Cambridge, where he developed novel high-performing nanomaterials for drug delivery and cancer treatment. With a decade of experience in particle production and characterisation across a range of scales, Ben is now focussed on the field of microfluidics, working extensively with customers to develop custom microfluidic systems and manufacturing methodologies. Ben has worked on applications ranging from drug encapsulation in micro and nanoparticles to surface functionalised microbeads for biological applications.

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.